Skip to main content
Top
Published in: Endocrine 3/2015

01-04-2015 | Endocrine Genetics/Epigenetics

The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma (PPARG) gene in relation to obesity and metabolic phenotypes in a Taiwanese population

Authors: Tun-Jen Hsiao, Eugene Lin

Published in: Endocrine | Issue 3/2015

Login to get access

Abstract

Obesity is considered as an important public health problem in the world. Although the association of a common single nucleotide polymorphism (SNP), rs1801282 (Pro12Ala), in the peroxisome proliferator-activated receptor gamma (PPARG) gene with obesity has been reported in various populations, these data are not conclusive. This study aimed to reassess whether the PPARG rs1801282 SNP is linked with obesity and obesity-related metabolic traits in a Taiwanese population. A total of 674 Taiwanese subjects with general health examinations were genotyped. The rs1801282 genotype was determined by the Taqman SNP genotyping assay. Obesity-related metabolic traits such as triglyceride, waist circumference, systolic and diastolic blood pressure, total cholesterol, and fasting glucose were measured. The PPARG rs1801282 SNP did not exhibit any significant association with obesity among the complete sample population. However, sex-stratified analyses revealed an effect on overweight in female participants where the carriers of the combined CG and GG genotypes had a higher risk to overweight than those with the CC homozygotes (OR = 4.05; 95 % CI = 1.28–12.83; P = 0.017). Compared to the carriers of CC homozygotes, BMI was significantly higher for the carriers of the combined CG and GG genotypes in the female subjects (24.4 ± 3.7 vs. 23.5 ± 3.8 kg/m2; P = 0.033). In addition, the carriers of the CC homozygotes had a higher total cholesterol level than those with the combined CG and GG genotypes in the female subjects (197.0 ± 37.3 vs. 180.7 ± 33.7 mg/dl; P = 0.026). Our study indicates that PPARG rs1801282 may significantly predict overweight, BMI, and total cholesterol in female but not male Taiwanese subjects.
Literature
1.
go back to reference X. Formiguera, A. Cantón, Obesity: epidemiology and clinical aspects. Best Pract. Res. Clin. Gastroenterol. 18(6), 1125–1146 (2004)CrossRefPubMed X. Formiguera, A. Cantón, Obesity: epidemiology and clinical aspects. Best Pract. Res. Clin. Gastroenterol. 18(6), 1125–1146 (2004)CrossRefPubMed
3.
go back to reference P. Hossain, Obesity and diabetes in the developing world—a growing challenge. N. Engl. J. Med. 356(3), 973–974 (2007)CrossRef P. Hossain, Obesity and diabetes in the developing world—a growing challenge. N. Engl. J. Med. 356(3), 973–974 (2007)CrossRef
4.
go back to reference A.J. Vidal-Puig, R.V. Considine, M. Jimenez-Liñan, A. Werman, W.J. Pories, J.F. Caro, J.S. Flier, Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest. 99(10), 2416–2422 (1997)CrossRefPubMedCentralPubMed A.J. Vidal-Puig, R.V. Considine, M. Jimenez-Liñan, A. Werman, W.J. Pories, J.F. Caro, J.S. Flier, Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest. 99(10), 2416–2422 (1997)CrossRefPubMedCentralPubMed
5.
go back to reference N. Latruffe, J. Vamecq, Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism. Biochimie 79(2–3), 81–94 (1997)CrossRefPubMed N. Latruffe, J. Vamecq, Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism. Biochimie 79(2–3), 81–94 (1997)CrossRefPubMed
6.
go back to reference S.S. Deeb, L. Fajas, M. Nemoto, J. Pihlajamaki, L. Mykkanen, J. Kuusisto, M. Laakso, W. Fujimoto, J. Auwerx, A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 20(3), 284–287 (1998)CrossRefPubMed S.S. Deeb, L. Fajas, M. Nemoto, J. Pihlajamaki, L. Mykkanen, J. Kuusisto, M. Laakso, W. Fujimoto, J. Auwerx, A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 20(3), 284–287 (1998)CrossRefPubMed
7.
go back to reference J. Masugi, Y. Tamori, H. Mori, T. Koike, M. Kasuga, Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione- induced adipogenesis. Biochem. Biophys. Res. Commun. 268(1), 178–182 (2000)CrossRefPubMed J. Masugi, Y. Tamori, H. Mori, T. Koike, M. Kasuga, Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione- induced adipogenesis. Biochem. Biophys. Res. Commun. 268(1), 178–182 (2000)CrossRefPubMed
8.
go back to reference M. Stumvoll, H. Häring, The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes 51(8), 2341–2347 (2002)CrossRefPubMed M. Stumvoll, H. Häring, The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes 51(8), 2341–2347 (2002)CrossRefPubMed
9.
go back to reference A.C. Pereira, R. Oliveira, A.C. Castro, R. Fernandes, Does Pro(12)Ala Polymorphism Enhance the Physiological Role of PPARγ2? PPAR Res. 2013, 401274 (2013)CrossRefPubMedCentralPubMed A.C. Pereira, R. Oliveira, A.C. Castro, R. Fernandes, Does Pro(12)Ala Polymorphism Enhance the Physiological Role of PPARγ2? PPAR Res. 2013, 401274 (2013)CrossRefPubMedCentralPubMed
10.
go back to reference B.A. Beamer, C.J. Yen, R.E. Andersen, D. Muller, D. Elahi, L.J. Cheskin, R. Andres, J. Roth, A.R. Shuldiner, Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes 47(11), 1806–1808 (1998)CrossRefPubMed B.A. Beamer, C.J. Yen, R.E. Andersen, D. Muller, D. Elahi, L.J. Cheskin, R. Andres, J. Roth, A.R. Shuldiner, Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes 47(11), 1806–1808 (1998)CrossRefPubMed
11.
go back to reference J.L.G. Sánchez, M.S. Ríos, C.F. Perez, M. Laakso, M.T.M. Larrad, Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur. J. Endocrinol. 147(4), 495–501 (2002)CrossRef J.L.G. Sánchez, M.S. Ríos, C.F. Perez, M. Laakso, M.T.M. Larrad, Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur. J. Endocrinol. 147(4), 495–501 (2002)CrossRef
12.
go back to reference S. Ben Ali, F. Ben Yahia, Y. Sediri, A. Kallel, B. Ftouhi, M. Feki, M. Elasmi, S. Haj-Taieb, O. Souheil, H. Sanhagi, H. Slimane, R. Jemaa, N. Kaabachi, Gender-specific effect of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma-2 gene on obesity risk and leptin levels in a Tunisian population. Clin. Biochem. 42(16–17), 1642–1647 (2009)CrossRefPubMed S. Ben Ali, F. Ben Yahia, Y. Sediri, A. Kallel, B. Ftouhi, M. Feki, M. Elasmi, S. Haj-Taieb, O. Souheil, H. Sanhagi, H. Slimane, R. Jemaa, N. Kaabachi, Gender-specific effect of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma-2 gene on obesity risk and leptin levels in a Tunisian population. Clin. Biochem. 42(16–17), 1642–1647 (2009)CrossRefPubMed
13.
go back to reference H. Mirzaei, S.M. Akrami, T. Golmohammadi, M. Doosti, R. Heshmat, M. Nakhjavani, P. Amiri, Polymorphism of Pro12Ala in the peroxisome proliferator-activated receptor gamma2 gene in Iranian diabetic and obese subjects. Metab. Syndr. Relat. Disord. 7(5), 453–458 (2009)CrossRefPubMed H. Mirzaei, S.M. Akrami, T. Golmohammadi, M. Doosti, R. Heshmat, M. Nakhjavani, P. Amiri, Polymorphism of Pro12Ala in the peroxisome proliferator-activated receptor gamma2 gene in Iranian diabetic and obese subjects. Metab. Syndr. Relat. Disord. 7(5), 453–458 (2009)CrossRefPubMed
14.
go back to reference J. Prakash, N. Srivastava, S. Awasthi, C. Agarwal, S. Natu, N. Rajpal, B. Mittal, Association of PPAR-γ gene polymorphisms with obesity and obesity-associated phenotypes in North Indian population. Am. J. Hum. Biol. 24(4), 454–459 (2012)CrossRefPubMed J. Prakash, N. Srivastava, S. Awasthi, C. Agarwal, S. Natu, N. Rajpal, B. Mittal, Association of PPAR-γ gene polymorphisms with obesity and obesity-associated phenotypes in North Indian population. Am. J. Hum. Biol. 24(4), 454–459 (2012)CrossRefPubMed
15.
go back to reference S.P. Bhatt, A. Misra, M. Sharma, K. Luthra, R. Guleria, R.M. Pandey, N.K. Vikram, Ala/Ala genotype of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-γ2 gene is associated with obesity and insulin resistance in Asian Indians. Diabetes Technol. Ther. 14(9), 828–834 (2012)CrossRefPubMedCentralPubMed S.P. Bhatt, A. Misra, M. Sharma, K. Luthra, R. Guleria, R.M. Pandey, N.K. Vikram, Ala/Ala genotype of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-γ2 gene is associated with obesity and insulin resistance in Asian Indians. Diabetes Technol. Ther. 14(9), 828–834 (2012)CrossRefPubMedCentralPubMed
16.
go back to reference O. Vaccaro, F.P. Mancini, G. Ruffa, L. Sabatino, V. Colantuoni, G. Riccardi, Pro12Ala mutation in the peroxisome proliferator-activated receptor gamma2 (PPARgamma2) and severe obesity: a case-control study. Int. J. Obes. Relat. Metab. Disord. 24(9), 1195–1199 (2000)CrossRefPubMed O. Vaccaro, F.P. Mancini, G. Ruffa, L. Sabatino, V. Colantuoni, G. Riccardi, Pro12Ala mutation in the peroxisome proliferator-activated receptor gamma2 (PPARgamma2) and severe obesity: a case-control study. Int. J. Obes. Relat. Metab. Disord. 24(9), 1195–1199 (2000)CrossRefPubMed
17.
go back to reference E.Y. Oh, K.M. Min, J.H. Chung, Y.K. Min, M.S. Lee, K.W. Kim, M.K. Lee, Significance of Pro12Ala mutation in peroxisome proliferator-activated receptor-gamma2 in Korean diabetic and obese subjects. J. Clin. Endocrinol. Metab. 85(5), 1801–1804 (2000)PubMed E.Y. Oh, K.M. Min, J.H. Chung, Y.K. Min, M.S. Lee, K.W. Kim, M.K. Lee, Significance of Pro12Ala mutation in peroxisome proliferator-activated receptor-gamma2 in Korean diabetic and obese subjects. J. Clin. Endocrinol. Metab. 85(5), 1801–1804 (2000)PubMed
18.
go back to reference K. Clement, S. Hercberg, B. Passinge, P. Galan, M. Varroud-Vial, A.R. Shuldiner, B.A. Beamer, G. Charpentier, B. Guy-Grand, P. Froguel, C. Vaisse, The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes. Int. J. Obes. Relat. Metab. Disord. 24(3), 391–393 (2000)CrossRefPubMed K. Clement, S. Hercberg, B. Passinge, P. Galan, M. Varroud-Vial, A.R. Shuldiner, B.A. Beamer, G. Charpentier, B. Guy-Grand, P. Froguel, C. Vaisse, The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes. Int. J. Obes. Relat. Metab. Disord. 24(3), 391–393 (2000)CrossRefPubMed
19.
go back to reference M. Ghoussaini, D. Meyre, S. Lobbens, G. Charpentier, K. Clément, M.A. Charles, M. Tauber, J. Weill, P. Froguel, Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population. BMC Med. Genet. 6, 11 (2005)CrossRefPubMedCentralPubMed M. Ghoussaini, D. Meyre, S. Lobbens, G. Charpentier, K. Clément, M.A. Charles, M. Tauber, J. Weill, P. Froguel, Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population. BMC Med. Genet. 6, 11 (2005)CrossRefPubMedCentralPubMed
20.
go back to reference M.M. Swarbrick, C.M. Chapman, B.M. McQuillan, J. Hung, P.L. Thompson, J.P. Beilby, A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-gamma 2 is associated with combined hyperlipidaemia in obesity. Eur. J. Endocrinol. 144(3), 277–282 (2001)CrossRefPubMed M.M. Swarbrick, C.M. Chapman, B.M. McQuillan, J. Hung, P.L. Thompson, J.P. Beilby, A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-gamma 2 is associated with combined hyperlipidaemia in obesity. Eur. J. Endocrinol. 144(3), 277–282 (2001)CrossRefPubMed
21.
go back to reference F.F. Carlos, J. Silva-Nunes, O. Flores, M. Brito, G. Doria, L. Veiga, P.V. Baptista, Association of FTO and PPARG polymorphisms with obesity in Portuguese women. Diabetes Metab. Syndr. Obes. 6, 241–245 (2013)PubMedCentralPubMed F.F. Carlos, J. Silva-Nunes, O. Flores, M. Brito, G. Doria, L. Veiga, P.V. Baptista, Association of FTO and PPARG polymorphisms with obesity in Portuguese women. Diabetes Metab. Syndr. Obes. 6, 241–245 (2013)PubMedCentralPubMed
22.
go back to reference T.J. Hsiao, Y. Hwang, C.H. Liu, H.M. Chang, E. Lin, Association of the C825T polymorphism in the GNB3 gene with obesity and metabolic phenotypes in a Taiwanese population. Genes Nutr. 8(1), 137–144 (2013)CrossRefPubMedCentralPubMed T.J. Hsiao, Y. Hwang, C.H. Liu, H.M. Chang, E. Lin, Association of the C825T polymorphism in the GNB3 gene with obesity and metabolic phenotypes in a Taiwanese population. Genes Nutr. 8(1), 137–144 (2013)CrossRefPubMedCentralPubMed
24.
go back to reference L.S. Wu, C.H. Hsieh, D. Pei, Y.J. Hung, S.W. Kuo, E. Lin, Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPAR{gamma} and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes. Nephrol. Dial. Transplant. 24(11), 3360–3366 (2009)CrossRefPubMed L.S. Wu, C.H. Hsieh, D. Pei, Y.J. Hung, S.W. Kuo, E. Lin, Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPAR{gamma} and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes. Nephrol. Dial. Transplant. 24(11), 3360–3366 (2009)CrossRefPubMed
25.
go back to reference D.J. Hsiao, L.S. Wu, S.Y. Huang, E. Lin, Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene. Pharmacogenet. Genomics 19(9), 730–733 (2009)CrossRefPubMed D.J. Hsiao, L.S. Wu, S.Y. Huang, E. Lin, Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene. Pharmacogenet. Genomics 19(9), 730–733 (2009)CrossRefPubMed
26.
go back to reference R. Valve, K. Sivenius, R. Miettinen, J. Pihlajamäki, A. Rissanen, S.S. Deeb, J. Auwerx, M. Uusitupa, M. Laakso, Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J. Clin. Endocrinol. Metab. 84(10), 3708–3712 (1999)PubMed R. Valve, K. Sivenius, R. Miettinen, J. Pihlajamäki, A. Rissanen, S.S. Deeb, J. Auwerx, M. Uusitupa, M. Laakso, Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J. Clin. Endocrinol. Metab. 84(10), 3708–3712 (1999)PubMed
27.
go back to reference T.J. Hsiao, E. Lin, Evaluation of the glutamine 27 glutamic acid polymorphism in the adrenoceptor beta 2 surface gene on obesity and metabolic phenotypes in Taiwan. J. Investig. Med. 62(2), 310–315 (2014)PubMed T.J. Hsiao, E. Lin, Evaluation of the glutamine 27 glutamic acid polymorphism in the adrenoceptor beta 2 surface gene on obesity and metabolic phenotypes in Taiwan. J. Investig. Med. 62(2), 310–315 (2014)PubMed
28.
go back to reference T.J. Hsiao, Y. Hwang, H.M. Chang, E. Lin, Association of the rs6235 variant in the proprotein convertase subtilisin/kexin type 1 (PCSK1) gene with obesity and related traits in a Taiwanese population. Gene 533(1), 32–37 (2014)CrossRefPubMed T.J. Hsiao, Y. Hwang, H.M. Chang, E. Lin, Association of the rs6235 variant in the proprotein convertase subtilisin/kexin type 1 (PCSK1) gene with obesity and related traits in a Taiwanese population. Gene 533(1), 32–37 (2014)CrossRefPubMed
29.
go back to reference H.Y. Lane, G.E. Tsai, E. Lin, Assessing gene–gene interactions in pharmacogenomics. Mol. Diagn. Ther. 16(1), 15–27 (2012)CrossRefPubMed H.Y. Lane, G.E. Tsai, E. Lin, Assessing gene–gene interactions in pharmacogenomics. Mol. Diagn. Ther. 16(1), 15–27 (2012)CrossRefPubMed
30.
go back to reference E. Lin, D. Pei, Y.J. Huang, C.H. Hsieh, L.S. Wu, Gene-gene interactions among genetic variants from obesity candidate genes for nonobese and obese populations in type 2 diabetes. Genet. Test Mol. Biomark. 13(4), 485–493 (2009)CrossRef E. Lin, D. Pei, Y.J. Huang, C.H. Hsieh, L.S. Wu, Gene-gene interactions among genetic variants from obesity candidate genes for nonobese and obese populations in type 2 diabetes. Genet. Test Mol. Biomark. 13(4), 485–493 (2009)CrossRef
31.
go back to reference Y.J. Liou, Y.M. Bai, E. Lin, J.Y. Chen, T.T. Chen, C.J. Hong, S.J. Tsai, Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. Pharmacogenomics J. 12(1), 54–61 (2012)CrossRefPubMed Y.J. Liou, Y.M. Bai, E. Lin, J.Y. Chen, T.T. Chen, C.J. Hong, S.J. Tsai, Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. Pharmacogenomics J. 12(1), 54–61 (2012)CrossRefPubMed
Metadata
Title
The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma (PPARG) gene in relation to obesity and metabolic phenotypes in a Taiwanese population
Authors
Tun-Jen Hsiao
Eugene Lin
Publication date
01-04-2015
Publisher
Springer US
Published in
Endocrine / Issue 3/2015
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0407-7

Other articles of this Issue 3/2015

Endocrine 3/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.